Immatics Investor Relations Material
Latest events
Study Update
Immatics
Q4 2024
27 Mar, 2025
Q3 2024
18 Nov, 2024
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Immatics N.V.
Access all reports
Immatics N.V. is a clinical-stage biopharmaceutical company dedicated to the discovery and development of T cell redirecting immunotherapies aimed at treating cancer. The company's innovative approach combines the identification of true targets for cancer immunotherapies with the development of suitable T cell receptors. The company is headquartered in Tübingen, Germany, and its shares are listed on the Nasdaq.
Latest articles
)
500 Years of Craft, One Family Legacy: Beretta Holding's Global Expansion
How Beretta Holding managed to transform from a 16th-century gun barrel producer into a global industrial group while preserving 500 years of legacy.
27 Jun 2025
)
Shuntaro Furukawa: The Sixth President of Nintendo
Shuntaro Furukawa, Nintendo's sixth president, went from a childhood fan to leading the company through global expansion and the launch of Switch 2.
23 Jun 2025
)
Nintendo: From Game Boy and Pokémon to Switch 2 and Mario Kart
Nintendo went from card maker to cultural icon, shaping modern entertainment through hardware innovation and world-famous characters.
19 Jun 2025
Ticker symbol
IMTX
Country
🇺🇸 United States